Textbook Notes (368,317)
Canada (161,798)
Psychology (1,468)
PSYCH 2AP3 (97)
Chapter 17

Chapter 17.docx

7 Pages
125 Views
Unlock Document

Department
Psychology
Course
PSYCH 2AP3
Professor
Richard B Day
Semester
Fall

Description
Psych 2AP3: Abnormal Psychology – Major Disorders Chapter 17: Therapy An Overview of Treatment - Why do people seek therapy?  Stressful current life circumstances: experiencing sudden and highly stressful situations  People with long standing problems: seek psychological assistance out of dissatisfaction and despair  Reluctant clients: entering therapy through indirect route. Males are more reluctant to enter therapy than females  People who seek personal growth: not lived up to own expectation - Who provides psychotherapeutic services?  Physicians, clergy  Clinical psychologist, psychiatrists and clinical social workers  Psychiatrists can prescribe psychoactive medications  Psychiatrist differ from psychologist in their predilection for treating mental disorders with a biological approach whereas psychologists treat patients’ psychopathology by examining and changing patients’ behaviour and thought patterns - The therapeutic relationship  The therapeutic alliance: how well clients do in treatment is related to strength of the alliance they have with their therapists  Other qualities that enhance therapy:  Client’s motivation  Client’s expectation of receiving help  Gain new perspective  Safe environment 17.1 The World Around Us: Why Are Men So Reluctant to Enter Therapy? - Men are less able than women to recognize and label feelings of distress - Masculine stereotypes, giving up control - More poorly informed about treatment - Develop treatment that’s based on theories of how men are socialized and that provide a better fit for men constrained by gender-role expectations Measuring Success in Psychotherapy - Therapist’s impression of changes that have occurred - Client’s reports of change - Reports from the client’s family or friends - Comparison of pretreatment and post-treatment scores on personality tests or on other instruments designed to measure relevant facets of psychological functioning - Measures of change in selected overt behaviours - Objectifying and quantifying change: client self-monitoring and fMRIs - Would change occur anyway: disturbed people may improve over time for reasons that are not apparent - Can therapy be hurtful: positive, neutral or negative 17.2 Developments in Research: Using Brain Activation to Measure Therapeutic Change - fMRI: technique used to measure changes in activation in human brain - When certain areas of the brain are active, they require more oxygen What Therapeutic Approaches should be used? - Evidence-based treatment:  Drugs must receive approval  Drug has efficacy: it does what it is supposed to do in curing or relieving some target conditions  Randomized control trials: tests using voluntary and informed patients by randomly assigning patients to active or inactive (placebo)  Double-blind procedure: neither patient nor prescriber is informed which is to be administered  Manualized therapies: researchers tried to minimize variability in patients’ clinical outcomes that might result from characteristics of the therapist themselves (randomized controlled trial)  Efficacy studies have been criticized for testing treatments under the most ideal conditions  Effectiveness: extent to which a treatment leads to change under less than optimal conditions, similar to conditions in real-life clinical settings - Medication or Psychotherapy:  Psychopharmacology has lead to a more favourable hospital climate  Side effects, complexity of matching drug and dosage, medication change, isolation from other treatment, relapse - Combined treatments:  Medication and psychotherapy 17.3 The World Around Us: Osherhoff v. Chestnut Lodge - Therapist may be liable for failing to provide medication to patients with certain disorders for which medication is known to be effective Pharmacological Approaches to Treatment - Antipsychotic drugs:  Used to treat psychotic disorders such as schizophrenia and psychotic mood disorders  Alleviate or reduce intensity of delusions and hallucinations by blocking dopamine receptors  Half-life: time taken for level of active drug to be reduced by 50%: less frequent dosing, less variation in concentration of drug in plasma, less severe withdrawals, risk drug will accumulate, increased sedation and psychomotor impairment  Daily or depot neuroleptics  Tardive dyskinesia: movement abnormality that is a delayed result of taking antipsychotic medication  May treat positive and negative symptoms of schizophrenia  Weight gain and diabetes  Clozapine: drop in white blood cells - Antidepressant drugs:  Selective serotonin reuptake inhibitors:  Inhibits reuptake of serotonin following release into synapse  Fewer side effects, not fatal in overdose  SNRIs: inhibits reuptake of serotonin and norepinephrine  Patients tend to improve after 3-5 weeks  Nausea, diarrhea, nervousness, insomnia and sexual problems  Monoamine oxidase inhibitors:  Inhibit the activity of monoamine oxidase, an enzyme present in the synaptic cleft that helps break down the monoamine neurotransmitters that have been released into the cleft  Must avoid foods rich in amino acid tyramine  Tricyclic antidepressants:  Inhibit reuptake of norepinephrine and serotonin  Other antidepressants:  Trazodone: inhibits reuptake of serotonin, sedating properties, can cause priapism in men  Bupropion: doesn’t block reuptake of serotonin or norepinephrine, but increases noradrenergic function, doesn’t inhibit sexual function  Mirtazapine: facilitates serotonin and norepinephrine neurotransmission, weight gain  Using antidepressants to treat anxiety disorders, bulimia, and personality disorders:  SSRIs: panic disorder, social phobia, generalized anxiety disorder, OCD, bulimia, borderline personality disorders  Tricyclic antidepressants: bulimia - Anti-anxiety drugs:  Benzodiazepines:  Brief treatment of acute anxiety and agitation  Rapidly absorbed from digestive tract and work quickly  Help quell anxiety, sleep-inducing agent  Dependency, withdrawal (seizures)  High relapse rates  Enhance activity of GABA receptors, limbic system  Other anti-anxiety medications:  Busiprone: serotonergic functioning, non-sedating, low dependency, not useful in acute situations - Lithium and other mood-stabilizing drugs:  Bipolar disorder, depression  May affect electrolyte balances that alter activities of neurotransmitters  70-80% show improvements after 2-3 weeks  Preventing future episodes of mania  Relapse  Side effects: increased thirst, gastrointestinal difficulties, weight gain, tremor, fatigue  Toxic if recommended dose is exceeded or if kidneys fail to excrete  Other mood-stabiliz
More Less

Related notes for PSYCH 2AP3

Log In


OR

Join OneClass

Access over 10 million pages of study
documents for 1.3 million courses.

Sign up

Join to view


OR

By registering, I agree to the Terms and Privacy Policies
Already have an account?
Just a few more details

So we can recommend you notes for your school.

Reset Password

Please enter below the email address you registered with and we will send you a link to reset your password.

Add your courses

Get notes from the top students in your class.


Submit